Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Iovance Biotherapeutics, Inc. - Common Stock (NQ:IOVA)

1.720 +0.030 (+1.78%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Iovance Biotherapeutics, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Why Shares of Iovance Biotherapeutics Jumped Monday
The company filed a Biologics License Application to the FDA for its lead therapy. 
Via The Motley Fool
Why Iovance Biotherapeutics Shares Are Trading Higher Today
Iovance Biotherapeutics (NASDAQ: IOVA) shares are trading higher on Monday after the company completed its Biologics License Application submission for lifileucel. 
Via Benzinga
Why Jounce Therapeutics Shares Are Trading Higher By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) shares jumped 59.6% to $0.2513. Crown Electrokinetics said it has entered into an agreement with a leading infrastructure solutions provider. 
Via Benzinga
Analyst Expectations for Iovance Biotherapeutics's Future
Via Benzinga
Expert Ratings for Iovance Biotherapeutics
Via Benzinga
The Latest Analyst Ratings for Iovance Biotherapeutics
Via Benzinga
What 6 Analyst Ratings Have To Say About Iovance Biotherapeutics
Via Benzinga
What 4 Analyst Ratings Have To Say About Iovance Biotherapeutics
Via Benzinga
Why Motorsport Games Shares Are Trading Lower By Over 10%; Here Are 20 Stocks Moving Premarket
Gainers Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) shares rose 38.5% to $2.05 in pre-market trading after gaining 8% on Friday. 
Via Benzinga
First Republic Bank, KeyCorp And Other Big Stocks Moving Higher In Monday's Pre-Market Session
U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 27, 2023
Via Benzinga
Recap: Iovance Biotherapeutics Q3 Earnings
Iovance Biotherapeutics (NASDAQ:IOVA) reported its Q3 earnings results on Thursday, November 3, 2022 at 04:01 PM. Here's what investors need to know about the announcement. 
Via Benzinga
American Express, Visa And Other Big Stocks Moving Higher In Friday's Pre-Market Session
U.S. stock futures traded slightly lower this morning. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
Why Iovance Biotherapeutics Stock Soared 12% Higher Today
A business, clinical, and regulatory update lifted the spirits of investors. 
Via The Motley Fool
Iovance Biotherapeutics Acquires Clinigen's IL-2 Product For Upfront £166.7M
Via Benzinga
Why Is Iovance Biotherapeutics (IOVA) Stock Soaring 20% Today?
Although Iovance Biotherapeutics cuts a speculative figure, IOVA stock managed to skyrocket on Monday off insider buying. 
Via InvestorPlace
Why Iovance Biotherapeutics Shares Are Trading Higher By Around 19%? Here Are 40 Stocks Moving In Monday's Mid-Day Session
Gainers Winc, Inc. (NYSE: WBEV) rose 88.5% to $0.3901 after dropping over 23% on Friday. Winc, last month, posted a Q3 loss of $0.33 per share. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
US Stocks Start Week On Lower Note; Dow Tumbles 250 Points
U.S. stocks traded lower this morning, with the Dow Jones falling around 250 points on Monday. 
Via Benzinga
Iovance Biotherapeutics Stock Is Surging: Here's Why
Iovance Biotherapeutics Inc (NASDAQ: IOVA) shares are trading higher Monday following recent insider buying from Director Wayne Rothbaum. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
$65 Million Bet On Iovance Biotherapeutics? Check Out These 3 Stocks Insiders Are Buying
Although US stocks closed mixed on Friday, there were a few notable insider trades. 
Via Benzinga
NIO To Surge Around 105%? Plus Keybanc Predicts $165 For This Stock
Keybanc raised the price target on AMETEK, Inc. (NYSE: AME) from $145 to $165. Keybanc analyst Steve Barger maintained an Overweight rating on the stock. AMETEK shares rose 0.9% to close at $139.32 on... 
Via Benzinga
Why Iovance Biotherapeutics Is Crashing Today
The FDA is asking the drug development outfit for more information regarding its tumor-infiltrating lymphocyte therapy. 
Via The Motley Fool
Iovance Biotherapeutics Pushes FDA Rolling Submission Deadline Into Next Year For Its Lead Skin Cancer Candidate
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
It's time to start closing out the trading week with a dive into the biggest pre-market stock movers for Friday morning! 
Via InvestorPlace
Why Infinity Pharmaceuticals Shares Tumbled Around 38%; Here Are 79 Biggest Movers From Yesterday
Gainers Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT) shares surged 113.8% to settle at $20.10 on Monday. Indivior PLC agreed to acquire Opiant Pharmaceuticals for $20.00 per share in cash, plus... 
Via Benzinga
Preview: Iovance Biotherapeutics's Earnings
Iovance Biotherapeutics (NASDAQ:IOVA) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 31, 2022
Upgrades 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback